CRN04894, now atumelnant, lowers urinary cortisol in patient group
CRN04894, now being called atumelnant, quickly lowered urine cortisol levels in five people with ACTH-dependent Cushing’s syndrome taking part in a clinical trial, according to interim study findings. The open-label Phase 1b/2a trial (NCT05804669), which is being conducted at the National Institutes of Health (NIH) in Maryland, still…